Journey Medical (DERM)
(Delayed Data from NSDQ)
$4.83 USD
+0.32 (7.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.87 +0.04 (0.83%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.83 USD
+0.32 (7.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.87 +0.04 (0.83%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth B Momentum F VGM
Zacks News
GSK's Jemperli Gets EU Nod for Endometrial Cancer Expanded Use
by Zacks Equity Research
GSK's Jemperli combo receives the European Commission's marketing authorization as a frontline treatment for certain types of primary advanced/recurrent endometrial cancer.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical
by Zacks Equity Research
Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.
Pfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EU
by Zacks Equity Research
Pfizer's (PFE) targeted immunotherapy, Elrexfio, for treating heavily pretreated adults with relapsed/refractory multiple myeloma gets EC's conditional marketing authorization.
Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails
by Zacks Equity Research
The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
Relative Price Strength Makes These 5 Stocks Excellent Buys
by Nilanjan Choudhury
WING, JAKK, NSIT, GIII and DERM are five stocks with explosive relative price strength.
The Zacks Analyst Blog Highlights Beacon Roofing Supply, TopBuild, Journey Medical, and Shift4
by Zacks Equity Research
Beacon Roofing Supply, TopBuild, Journey Medical, and Shift4 are included in this Analyst Blog.
Journey Medical (DERM) Up on Update for Skin Disease Candidate
by Zacks Equity Research
Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.
4 Growth Stocks to Buy Ahead of a Strong Year-End Rally
by Tirthankar Chakraborty
With the Fed likely to trim interest rates along with seasonal tailwinds, growth stocks like Beacon Roofing Supply (BECN), TopBuild (BLD), Journey Medical (DERM) and Shift4 Payments (FOUR) are poised to gain strength.
Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great Choice
by Zacks Equity Research
Does Journey Medical Corporation (DERM) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Journey Medical Corporation (DERM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.
Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights
by Zacks Equity Research
Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -35.29% and 15.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Q2 Earnings Miss Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -7.14% and 3.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 18.82% and 12.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%
by Zacks Equity Research
Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.
Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More
by Zacks Equity Research
Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.
Journey Medical (DERM) Up on Rosacea Candidate's Positive Data
by Zacks Equity Research
Journey Medical's (DERM) phase I study, assessing the impact of DFD-29 on the microbial flora of healthy adults, obtains its primary endpoints.
Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -29.55% and 23.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -62.16% and 4.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (DERM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -67.65% and 11.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 4.35% and 22.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?